Story
Ben & Jerry's Founders Explore ESOP-Based Carve-Out With KKR Executive, WSJ Reports

The founders of Ben & Jerry's are exploring a deal to separate the iconic ice cream brand from its parent company through a potential carve-out led by a senior executive at private equity firm KKR, according to a report from The Wall Street Journal.
The Proposed Structure
The discussions involve KKR's global co-head of private equity, Pete Stavros, and Ben & Jerry's co-founder Ben Cohen, the WSJ reported on Monday. Central to the proposal is a plan to restructure the business under an employee stock-ownership plan (ESOP).
An ESOP structure would grant equity to the company's rank-and-file employees while also providing potential tax benefits for the business, the report added. This model would represent a significant shift in the brand's ownership and governance.
Context and Implications
AdBen & Jerry's is currently part of Unilever's ice cream division, which the consumer goods giant is in the process of spinning off into a standalone company. That division also includes major brands like Magnum. A potential carve-out of one of its most valuable brands could significantly impact the valuation and strategic direction of the newly independent ice cream business for investors.
The involvement of a high-profile private equity figure like Stavros is notable. The ESOP model also aligns with the socially progressive ethos that has long defined the Ben & Jerry's brand since its founding.
Sourcing and Company Response
The initial report from The Wall Street Journal cited both Stavros and Cohen as sources for the ongoing discussions. According to a subsequent report from Reuters, KKR, Ben & Jerry's, and the parent ice cream division did not immediately respond to requests for comment on the matter.
Read next
More on Stocks
Tesla's 'No-Deal' Valuation Estimated in $355–$372 Range Amid SpaceX Merger Talk
Analysis suggests Tesla's current stock price includes a premium of roughly $20 to $40 per share based on potential merger talks with SpaceX. The electric vehicle maker's implied price without the deal is estimated to be between $355 and $372.

Lycia Therapeutics Raises $365 Million in Upsized Nasdaq IPO
Clinical-stage biotech firm Lycia Therapeutics has closed its upsized initial public offering, raising approximately $365.1 million after underwriters fully exercised their option to purchase additional shares.

Broadcom, Major Banks Unveil $63 Billion AI Compute Financing for Anthropic
A consortium including Bank of America, Blackstone, Citi, and Morgan Stanley has committed $63 billion to finance the sale of Broadcom's AI hardware to Anthropic. The deal highlights the immense capital required for AI infrastructure and secures a long-term compute roadmap for the AI developer.

Eli Lilly Can Continue Weight-Loss Drug Ads After Judge Denies Novo Nordisk Injunction
A U.S. federal judge has rejected Novo Nordisk's request to block rival Eli Lilly's advertisements for its Zepbound and Mounjaro drugs, a key development in the battle for the multi-billion dollar obesity treatment market.